Stereotaxis Inc (STXS) 2026 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good afternoon. Thank you for joining us for Stereotaxis' second-quarter 2026 earnings conference call. Certain statements during the conference call and question-and-answer period to follow may relate to future events, expectations, and as such, constitute towards forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

    各位下午好。感謝各位參加 Stereotaxis 2026 年第二季財報電話會議。在本次電話會議以及隨後的問答環節中,部分陳述可能涉及未來事件與預期,因此構成《1995 年私人證券訴訟改革法》所界定的前瞻性陳述。

  • Such statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company in the future to be materially different from the statements that the company's executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10-K or 10-Q. We assume no duty to update this statement. (Operator Instructions) As a reminder, today's call is being recorded.

    此類陳述涉及已知與未知的風險、不確定性及其他因素,可能導致公司未來的實際結果、表現或成就與公司管理層今日所作陳述存在重大差異。這些風險已在我們向美國證券交易委員會(SEC)提交的公開文件中詳細說明,包括我們最新的 Form 10-K 或 10-Q 定期報告。我們不承擔更新本聲明的任何義務。(接線員指示) 提醒各位,今天的電話會議將被錄音。

  • It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis. Please go ahead.

    現在我很榮幸把會議交給本次主持人——Stereotaxis 董事長兼執行長 David Fischel。請開始。

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • Thank you, operator, and good afternoon, everyone. On our last call, we discussed in detail the structural transformations taking place at Stereotaxis. We just celebrated a particularly milestone-rich period with regulatory approvals for a new robot, both therapeutic and diagnostic catheters, and a digital surgery system.

    謝謝接線員,各位下午好。在上次電話會議中,我們詳細討論了 Stereotaxis 正在進行的結構性轉型。我們剛剛慶祝了一段里程碑特別密集的時期,取得了新型機器人、治療與診斷導管,以及數位手術系統的監管核准。

  • These products individually and collectively as a synergistic ecosystem create an attractive foundation for us to scale commercialization with reduced barriers to adoption and a much more attractive business model. During the second-quarter, Stereotaxis reached an important commercial inflection point as our expanded product offering is now generating accelerating adoption. It is still just the initial green shoots of commercial success, but the early experience and feedback provides confidence in sustained progress.

    這些產品無論單獨或共同作為一個具協同效應的生態系,皆為我們擴大商業化奠定了具吸引力的基礎,降低採用門檻並帶來更具吸引力的商業模式。在第二季,隨著我們擴充的產品組合開始帶動加速採用,Stereotaxis 達到了一個重要的商業拐點。目前仍只是商業成功的初步萌芽,但早期的經驗與回饋讓我們對持續進展更具信心。

  • I'll discuss on today's call the primary areas of commercial progress, the feedback from the field, and our efforts to accelerate growth. I'll then share some additional updates on the robust pipeline of innovations that we continue to advance and that will drive a second wave of growth over the coming years. Kim will then share financial details for the quarter and we'll open the line for questions.

    在今天的電話會議中,我將討論商業進展的主要領域、來自市場端的回饋,以及我們加速成長的努力。接著我會分享我們持續推進的強勁創新產品管線的其他更新,這些創新將在未來幾年帶來第二波成長。之後 Kim 將分享本季的財務細節,並開放提問。

  • A key area of focus in the second-quarter was on the launch of MAGiC in the US following FDA approval in the first-quarter. While supply constrained and still just in the early adoption phase, that launch allows us to reach a multi-year high point in recurring revenue, which surpassed $6 million in the quarter, driven by over $1 million in robotic catheter revenue.

    第二季的一個重點工作,是在第一季取得 FDA 核准後於美國推出 MAGiC。儘管供應受限且仍處於早期採用階段,這次上市使我們的經常性收入達到多年高點,本季超過 600 萬美元,其中超過 100 萬美元來自機器人導管收入。

  • Our robotic catheter revenue is scaling significantly in both the US and Europe with nearly 300% sequential growth from the first to the second-quarter. We are in the early phase of adoption of MAGiC, with about a dozen US sites receiving hospital approval to purchase the catheter and beginning procedures in the second-quarter.

    我們的機器人導管收入在美國與歐洲均顯著擴張,從第一季到第二季的季增幅接近 300%。MAGiC 仍處於早期採用階段,約有十多家美國院所取得院內核准可採購該導管,並於第二季開始進行手術。

  • Several physicians sent me unprompted feedback as they started to use the catheter. 1 physician commented, MAGiC performs so much better than the old ablation catheter. Basically, you can more reliably target tissue and more effectively ablate the target tissue. It fundamentally changes the utility of the Stereotaxis system, more than doubling the value of having a robot.

    多位醫師在開始使用該導管後主動向我提供回饋。有一位醫師評論說,MAGiC 的表現比舊款消融導管好太多。基本上,你可以更可靠地鎖定組織,並更有效地消融目標組織。它從根本上改變了 Stereotaxis 系統的效用,使擁有機器人的價值提升超過一倍。

  • Another physician, upon completing his first 10 procedures, mentioned that he is, loving it, and that the catheter is improving his efficiency significantly with a more stable and more powerful catheter delivering rapid, effective ablations. Another physician, after his first day of procedures, mentioned, wow, this catheter navigates well. You guys have something special.

    另一位醫師在完成前 10 例手術後提到,他非常喜歡,且該導管以更穩定、更強力的特性提供快速且有效的消融,顯著提升了他的效率。還有一位醫師在第一天手術後提到,哇,這支導管的導航性很好。你們做出了很特別的產品。

  • This feedback is highly encouraging. We have long known that the perception and value proposition of robotics in EP is only as good as the catheters available for use with the robot. Being tied to decades-old catheter that did not benefit from continued innovation limited our potential. It is very satisfying to see the innovations we took from concept to commercial reality benefit critical patients with complex arrhythmias and the physicians that treat them.

    這些回饋非常令人鼓舞。我們早就知道,在電生理(EP)領域,機器人技術的觀感與價值主張,取決於可與機器人搭配使用的導管品質。長期受限於數十年前的舊式導管、且未能受益於持續創新,限制了我們的潛力。看到我們將創新從概念推進到商業化落地,並讓罹患複雜心律不整的關鍵病患以及治療他們的醫師受益,令人非常欣慰。

  • It gives us confidence that our efforts to reestablish Stereotaxis on a healthy foundation and trajectory are off to a good start. We are continuing to methodically work through hospital approvals and initial launches of our robotic catheters across our US and European installed base. We expect the vast majority to shift from their historical dependency on J&J to our catheters within the next year.

    這讓我們更有信心:我們為重新建立 Stereotaxis 健全基礎與成長軌跡所做的努力,已經有了良好開端。我們正持續有條不紊地推進在美國與歐洲既有裝機基礎中的院內核准流程,以及機器人導管的初期上市導入。我們預期在未來一年內,絕大多數客戶將從過去對 J&J 的依賴轉向使用我們的導管。

  • While working through the commercial friction of transitioning each customer, we are putting significant effort into ramping manufacturing of catheters. Sales remain supply constrained as we work to increase output with catheters still on backlog as we receive more orders from customers than the supply we receive from our contract manufacturer, Osypka.

    在逐一協助每位客戶完成轉換、處理商業摩擦的同時,我們也投入大量心力提升導管的製造產能。在我們努力提高產出之際,銷售仍受供應限制;由於客戶下單量高於我們從合約製造商 Osypka 取得的供應量,導管仍處於積壓待交狀態。

  • We are seeing methodical progress in increasing supply and are separately reaching key milestones in establishing supply redundancy. These support our expectations of sustained growth in our catheter revenue stream, and we're guiding for an approximate $1 million incremental step up in catheter revenue in each of the next couple quarters, with significantly more opportunities beyond that in 2027.

    我們在提升供應方面看到循序漸進的進展,並且也在建立供應備援方面達成關鍵里程碑。這些進展支持我們對導管收入來源可持續成長的預期;我們指引未來接下來幾季中,每一季導管收入約可再增加 100 萬美元的增量階梯,且在 2027 年還有顯著更多的機會。

  • Shifting now to system revenue. There are two primary items to discuss, Synchrony and GenesisX. During the second-quarter, we received FDA clearance for the Synchrony system. As a reminder, Synchrony and SynX are our digital solutions that modernize the interventional surgical suite with enhanced workflow, remote connectivity, and smart AI capabilities. Synchrony serves as the cockpit for every robot, but also has an independent, much larger opportunity in non-robotic operating rooms.

    接著談系統收入。主要有兩項重點要討論:Synchrony 與 GenesisX。在第二季,我們取得了 Synchrony 系統的 FDA 核准。提醒各位,Synchrony 與 SynX 是我們的數位解決方案,透過強化工作流程、遠端連線與智慧 AI 能力,使介入手術室現代化。Synchrony 作為每一台機器人的駕駛艙,同時在非機器人手術室也有獨立且更大的市場機會。

  • Shortly after receiving regulatory clearance, we received orders for multiple systems from several hospitals. We shipped the first few systems in the second-quarter, have continued to ship systems in the third-quarter, and there are already several systems in daily clinical use. They're performing well in the field, and we have a pipeline of software feature enhancements over the coming months and years that will continue to expand the value proposition.

    在取得監管核准後不久,我們便收到多家醫院對多套系統的訂單。我們在第二季出貨了首批幾套系統,第三季持續出貨,且目前已有多套系統在臨床上每日使用。它們在現場表現良好;未來數月與數年我們也有一系列軟體功能強化的產品管線,將持續擴大其價值主張。

  • Without a significant dedicated sales effort, we are seeing organic interest that should support over $1 million in Synchrony system revenue each quarter for the next few quarters. Most excitingly, there are several hospitals that are planning or considering standardizing their catheter labs on Synchrony and SynX. While the current contribution of Synchrony is a nice but modest boost to revenue, the market opportunity is large and we intend to increase the sales effort as our pipeline builds and our manufacturing capacity matures.

    即使沒有投入大量專職銷售資源,我們仍看到自然形成的市場興趣,預期可在未來幾季每季支撐超過 100 萬美元的 Synchrony 系統收入。最令人振奮的是,有數家醫院正在規劃或評估將其導管實驗室標準化採用 Synchrony 與 SynX。雖然目前 Synchrony 的貢獻對營收而言是可喜但仍屬溫和的提升,但市場機會龐大;隨著我們的銷售管線累積、製造產能成熟,我們打算加大銷售投入。

  • As these initial installs mature, they will also start to drive service contract and Software-as-a-Service recurring revenue streams. Most impactful to system revenue over the coming few years will be scaling the adoption of our robotic technology. Our robotic technology has significant real-world validation with over 150,000 patients treated at over 100 leading hospitals globally.

    隨著這些初期裝機逐步成熟,它們也將開始帶動服務合約與軟體即服務(SaaS)的經常性收入來源。在未來幾年對系統收入影響最大者,將是擴大我們機器人技術的採用規模。我們的機器人技術已獲得顯著的真實世界驗證:全球超過 100 家頂尖醫院已為超過 15 萬名病患提供治療。

  • That said, we still have just a fraction of a percent market share in our beachhead market of electrophysiology and no presence yet in the larger interventional cardiology and neurointerventional fields. There is a market opportunity for many thousands of robotic systems across these markets. Our historical need to construct robotic labs was a major barrier to ever realizing that opportunity.

    即便如此,我們在作為灘頭堡市場的電生理領域市占率仍僅為不到百分之一的極小部分,且在更大的介入性心臟病學與神經介入領域尚未建立任何布局。在這些市場中,存在可容納數千套機器人系統的市場機會。過去我們必須建置機器人導管室的需求,是我們無法實現該機會的一大障礙。

  • GenesisX allows us to start envisioning a realistic way to scale robotic adoption much more significantly. Since we received regulatory clearance for GenesisX, we've been focused on how to ensure GenesisX can be installed alongside standard X-rays from leading manufacturers, removing the historical requirement that a robot only work with a specific modified X-ray.

    GenesisX 讓我們開始構想一條更為務實的路徑,以更大幅度擴大機器人採用規模。自從我們取得 GenesisX 的監管核准後,我們一直專注於如何確保 GenesisX 能夠與主要製造商的標準 X 光設備並行安裝,從而消除過往「機器人只能搭配特定改裝 X 光設備」的歷史性限制。

  • We focused our initial commercial launch on the early adopters who will demonstrate that potential and serve as reference sites for broad compatibility with various X-rays. We are pleased that in addition to the previously announced GenesisX purchase in Europe, we're able to announce our first GenesisX purchase in the US from an academic medical center.

    我們將初期商業化上市聚焦於早期採用者,他們將展示這項潛力,並作為各式 X 光設備廣泛相容性的示範與參考據點。我們很高興地宣布,除先前已公布在歐洲的 GenesisX 採購案外,我們也能宣布在美國由一家學術醫學中心完成的首筆 GenesisX 採購。

  • The system is expected to be installed this fall with a non-modified X-ray from one of the larger X-ray manufacturers. With that installation, we expect to declare formal compatibility with that manufacturer's X-ray. The construction of the new wing of the hospital in Europe, where GenesisX is scheduled to be installed, also seems to be finally back on track with installation expected prior to year-end.

    該系統預計將於今年秋季安裝,並搭配某家大型 X 光製造商的未改裝 X 光設備。隨著該次安裝完成,我們預期將正式宣告與該製造商 X 光設備的相容性。此外,歐洲該家醫院的新翼大樓建設(GenesisX 預定安裝於此)似乎也終於回到正軌,預計在年底前完成安裝。

  • We're continuing to advance several additional GenesisX sale or lease agreements that will further demonstrate the system being used in a variety of lab environments. With demonstration of GenesisX working reliably and compatibly with various X-rays, along with increased availability of MAGiC, we will initiate a more aggressive commercial launch of the technology.

    我們持續推進數項額外的 GenesisX 銷售或租賃協議,將進一步展示該系統可在多樣化的實驗室環境中使用。隨著 GenesisX 在各種 X 光設備上可靠運作並具備相容性的示範,加上 MAGiC 供應量提升,我們將啟動更積極的技術商業化推廣。

  • These initial green shoots of commercial success demonstrate the opportunity to build a highly successful business with our new product ecosystem. A proprietary catheter portfolio with its high margin razor blade business model has been central to our strategy and is now starting to become a material contributor. Accessibility of our robotic systems, such that we can reasonably scale to selling 10s and then 100s of robots a year is critical if we are to impact medicine in the way we should, and we have now begun that journey and will demonstrate the robot's performance in daily clinical use in the near term.

    這些初步的商業成功萌芽,展現了以我們全新產品生態系打造高度成功事業的機會。以高毛利的「剃刀與刀片」商業模式為核心的專有導管產品組合,一直是我們策略的關鍵,如今也開始成為實質性的貢獻來源。若要以我們應有的方式對醫療產生影響,機器人系統的可近性至關重要,使我們能合理擴展到每年銷售數十台、進而數百台機器人;我們如今已踏上這段旅程,並將在近期於日常臨床使用中展示機器人的表現。

  • This progress does not come easy and I want to recognize and congratulate the many Stereotaxis team members who make it possible. There are always hurdles and unforeseen challenges in the effort to pioneer new advanced technologies and to implement them in the complex healthcare market and demanding operating room environment. As a lean team working on multiple significant transitions in tandem, they're demonstrating our ability to rise to the challenge. Thank you everyone who makes this possible.

    這樣的進展並不容易,我想特別肯定並祝賀許多讓一切成真的 Stereotaxis 團隊成員。在開創先進新技術並將其導入複雜的醫療市場與高要求的手術室環境時,總會遇到障礙與不可預見的挑戰。作為一支精實團隊,同時推動多項重大轉型,他們正展現我們迎難而上的能力。感謝每一位讓這一切成為可能的人。

  • It is particularly exciting for me that we are driving this operational and commercial progress while not slowing down on a robust innovation effort. There is much going on in the background and we are energetically nurturing significant opportunities that will blossom over the next few years. Our efforts can be summarized in a few key categories.

    對我而言尤其令人振奮的是,我們在推動營運與商業進展的同時,並未放慢強勁的創新腳步。在幕後有許多工作正在進行,我們也正積極培育多項重大機會,將在未來幾年開花結果。我們的努力可歸納為幾個關鍵類別。

  • First, robot accessibility. We're advancing a future generation of the GenesisX robot that will be fully wireless, battery operated and mobile. Second, a more robust portfolio of EP catheter innovation. Most imminently here, we expect first-in-human procedures with MAGiC and Pulsed Field Ablation before the end of this year.

    第一,機器人可近性。我們正在推進下一代 GenesisX 機器人,將具備全無線、電池供電與可移動性。第二,更強健的電生理(EP)導管創新產品組合。在近期方面,我們預期在今年年底前以 MAGiC 與脈衝場消融(Pulsed Field Ablation)進行首次人體(first-in-human)手術。

  • Third, a pipeline of robotic systems and interventional devices for the broader interventional cardiology and neurointerventional fields. We're advancing regulatory submissions and reviews for the EMAGIN family of magnetic guide catheters and guidewires that will be driven by GenesisX. Even more significantly, we closed the previously announced Robocath acquisition in July and are energetically advancing their fully complementary and separate robotic system for endovascular device navigation with a vision of offering a full ecosystem that enables remote, automated, and fully robotic treatment of stroke and cardiovascular disease.

    第三,面向更廣泛介入心臟病學與神經介入領域的機器人系統與介入器械產品線。我們正推進 EMAGIN 系列磁性導引導管與導絲的監管申報與審查,該系列將由 GenesisX 驅動。更重要的是,我們已於 7 月完成先前公布的 Robocath 收購,並正積極推進其完全互補且獨立的血管內器械導航機器人系統,願景是提供完整生態系,實現遠端、自動化與全機器人化的中風與心血管疾病治療。

  • And fourth, AI efforts that will incorporate intelligent decision support features into Synchrony and automation to our robotic platforms. We will discuss these further on future calls and as they mature, but there is still much room to advance our technology in exciting ways that improve and expand our clinical impact and commercial opportunity.

    第四,AI 相關工作,將把智慧決策支援功能導入 Synchrony,並為我們的機器人平台加入自動化能力。我們將在未來的電話會議中、以及這些項目逐步成熟時進一步討論;但在以令人振奮的方式推進我們的技術、提升並擴大臨床影響與商業機會方面,仍有很大空間。

  • Our vision for what Stereotaxis can and will accomplish is becoming increasingly clear and tangible. The key puzzle pieces have come together in a remarkable fashion and we are enthusiastically advancing forward. Kim will now provide commentary on our financial results and then I'll make a few financial comments as well before opening the call to Q&A. Kim?

    我們對 Stereotaxis 能夠且將要達成的願景,正變得愈發清晰且具體。關鍵拼圖以非凡的方式逐一到位,我們也正滿懷熱忱地向前推進。接下來 Kim 將就我們的財務結果提供評論,之後我也會再補充幾點財務方面的看法,然後開放問答。Kim?

  • Kimberly Peery - Chief Financial Officer

    Kimberly Peery - Chief Financial Officer

  • Thank you, David, and good afternoon, everyone. Revenue for the second-quarter of 2026 totaled $7.7 million. Revenue in the quarter declined year-over-year due to the lack of a robotic system delivery in the quarter, but increased sequentially from the first-quarter due to significantly higher catheter revenue. System revenue of $1.5 million and recurring revenue of $6.2 million compared to $3 million and $5.8 million in the prior year's second-quarter.

    謝謝你,David,各位下午好。2026 年第二季營收合計為 770 萬美元。本季營收較去年同期下滑,原因是本季未交付任何機器人系統;但由於導管營收顯著提高,較第一季呈現季增。系統營收為 150 萬美元、經常性營收為 620 萬美元;相較之下,去年第二季分別為 300 萬美元與 580 萬美元。

  • System revenue in the current quarter includes modest revenue recognition from previously delivered Genesis systems and ancillary equipment and a notable contribution from the initial launch of Synchrony. Recurring revenue in the quarter reflects a significant increase in revenue from our new portfolio of robotically navigated catheters, up 270% sequentially and 450% year-over-year, countered by general pressure on procedures as we transition away from Johnson & Johnson and manufacturing of our catheters.

    本季系統營收包含先前已交付的 Genesis 系統與周邊設備所帶來的少量收入認列,以及 Synchrony 初期上市所帶來的顯著貢獻。本季經常性營收反映我們新一代機器人導航導管產品組合帶來的營收大幅增加,季增 270%、年增 450%;但同時也受到手術量普遍承壓的抵銷影響,因我們正逐步轉離強生(Johnson & Johnson)以及我們導管的製造。

  • Gross margin for the second-quarter of 2026 was 58% of revenue. Recurring revenue gross margin was 66% and system gross margin was 29%. Gross margins for both recurring revenue and systems are impacted by low manufacturing volumes. While we expect margins to remain at these approximate levels over the next few quarters, we see significant opportunity for margin expansion in 2027 and 2028.

    2026 年第二季毛利率為營收的 58%。經常性營收毛利率為 66%,系統毛利率為 29%。經常性營收與系統的毛利率皆受到製造量偏低的影響。雖然我們預期未來幾季毛利率將大致維持在這些水準附近,但我們看到在 2027 與 2028 年毛利率擴張的顯著機會。

  • Operating expenses in the quarter of $9.1 million included $2.5 million in non-cash charges for stock compensation expense, mark-to-market adjustment for acquisition-related contingent earn-out consideration, and amortization of acquired intangible assets. Excluding these non-cash charges, adjusted operating expenses were $6.6 million, consistent with a year-ago period when adjusting for a one-time employee retention tax credit received in the prior year.

    本季營業費用為 910 萬美元,其中包含 250 萬美元的非現金費用,涵蓋股票薪酬費用、與收購相關的或有分期對價(earn-out)之按市價評價調整,以及取得之無形資產攤銷。排除這些非現金費用後,調整後營業費用為 660 萬美元;若將去年同期一次性的員工留任稅額抵免(employee retention tax credit)影響調整後,該水準與去年同期一致。

  • Operating loss and net loss in the second-quarter of 2026 were $4.6 million and $4.5 million compared with $4 million and $3.8 million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash charges, were $2.1 million and $2 million, compared with $1.4 million and $1.3 million in the previous year. Negative free cash flow for the second-quarter was $3.7 million, consistent with the previous year. At June 30th, Stereotaxis had cash and cash equivalents of $10.5 million and no debt.

    2026 年第二季營業損失與淨損失分別為 460 萬美元與 450 萬美元,相較去年同期分別為 400 萬美元與 380 萬美元。本季調整後營業損失與調整後淨損失(排除非現金費用)分別為 210 萬美元與 200 萬美元,相較去年同期分別為 140 萬美元與 130 萬美元。第二季自由現金流為負 370 萬美元,與去年同期一致。截至 6 月 30 日,Stereotaxis 持有現金及約當現金 1,050 萬美元,且無負債。

  • I will now hand the call back to David.

    我現在把電話交回給 David。

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • Thank you, Kim. We expect continued momentum in recurring revenue driven by increased manufacturing supply and expanded adoption of our robotic catheter portfolio. Recurring revenue is anticipated to grow to approximately $7 million in the third-quarter and $8 million in the fourth-quarter of this year, with significant room for continued momentum in 2027 and beyond. System revenue has been weak in the first half of this year, and we expect the second half to be stronger with approximately $3 million in each of the third and fourth-quarters.

    謝謝你,Kim。我們預期在製造供應增加與機器人導管產品組合採用擴大帶動下,經常性營收將持續保持動能。預計經常性營收在今年第三季將成長至約 700 萬美元、第四季約 800 萬美元,並在 2027 年及之後仍有顯著的持續成長空間。系統營收在今年上半年表現疲弱,我們預期下半年將更強勁,第三季與第四季各約 300 萬美元。

  • From a financial perspective, we've maintained a lean operating budget while managing multiple product launches, ramping manufacturing, executing a strategic acquisition, and advancing a continued robust R&D effort. We are sensitive to subjecting investors to dilution and are confident we can advance our strategy on our current budget. We are internally modeling to reach cash flow profitability in the first half of 2027.

    從財務角度來看,我們在同時管理多項產品上市、提升製造產能、執行策略性併購,以及推進持續且強勁的研發投入之際,仍維持精實的營運預算。我們對讓投資人承受股權稀釋保持審慎,並有信心可在目前的預算下推進我們的策略。我們在內部模型中預估,將於 2027 年上半年達成現金流獲利。

  • As our recurring revenue ramps, the majority of incremental revenue flows to operating profit. This revenue ramp can be accomplished with our existing team, and as we reach cash flow profitability, we will reinvest our profits in our commercial organization supporting accelerated growth.

    隨著我們的經常性收入提升,大部分新增收入將流向營業利潤。這一收入提升可由我們現有團隊完成;而當我們達到現金流獲利時,我們將把利潤再投資於商業組織,以支持加速成長。

  • We will now take your questions. Operator, can you please open the line to Q&A?

    我們現在開始回答各位的提問。接線員,請開放問答線路。

  • Operator

    Operator

  • (Operator Instructions) Daniel Stauder, Citizens JMP.

    (接線員指示) Citizens JMP 的 Daniel Stauder。

  • Daniel Stauder - Analyst

    Daniel Stauder - Analyst

  • Just the first one on guidance. I appreciate the level of quarterly detail for recurring revenue and capital. I believe that puts the full year at about $35 million. I was hoping you could give us some more color on, one, your visibility, and two, your confidence in terms of hitting these numbers in the back half, and more broadly, what is assumed or contemplated in terms of catheter manufacturing improvements, as well as some capital adoption and installation timing as we think about these expectations.

    先問第一個,關於財測指引。我很感謝你們提供經常性收入與資本(設備)方面的季度細節。我認為這樣推算全年大約是 3,500 萬美元。我希望你們能再多補充一些資訊:第一,你們的能見度;第二,你們對於在下半年達成這些數字的信心程度;以及更廣泛地,當我們思考這些預期時,在導管製造改善方面、以及一些資本設備採用與安裝時程方面,假設或考量了哪些因素。

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • Thanks for the questions. We thought that would be kind of a helpful way to share our expectations. And the growth in recurring revenue is essentially all driven by adoption of our proprietary catheters, of kind of our robotically steered catheters. And there's obviously volatility in any given quarter in terms of things like the Map-iT catheters and procedure volume.

    謝謝你的提問。我們認為用這種方式分享我們的預期會比較有幫助。而經常性收入的成長基本上完全是由我們專有導管的採用所驅動,也就是我們的機器人導引導管。當然,在任何單一季度,像是 Map-iT 導管與手術量等因素都會帶來波動。

  • The third-quarter is generally a seasonally weak quarter in terms of procedures just because of summer vacations, particularly in Europe, but also in the US But generally, the growth is coming all from adoption of MAGiC, MAGiC Sweep, and in Europe we have kind of other catheters that we're able to also kind of supplement those. And so that's where all the growth comes from.

    第三季通常在手術量方面屬於季節性偏弱的季度,主要因為暑期假期,特別是在歐洲,但美國也是如此。不過整體而言,成長主要都來自 MAGiC、MAGiC Sweep 的採用;在歐洲我們還有其他一些導管,也能在某種程度上補充這些產品。因此,所有成長都來自於此。

  • We are looking at it both from a demand perspective and from a supply perspective, but in things like the third and fourth-quarter, it's really still driven essentially all by supply. And so we're still supply constrained. We have a backlog of catheter orders from customers, from many customers. And as we get catheters in from that supply, we're able to ship it kind of very quickly to customers and recognize revenue. And so that's kind of the main factor in our determination.

    我們同時從需求面與供給面來看,但在第三季與第四季這樣的期間,實際上幾乎完全仍是由供給所驅動。因此我們仍受限於供給。我們有來自客戶、且是許多客戶的導管訂單積壓。當我們從供應端取得導管後,就能相當快速地出貨給客戶並認列收入。因此,這是我們判斷的主要因素。

  • On the system side of things, it's a mix of both Synchrony and robotic systems. On the Synchrony side, we have been receiving, we have received orders that we've not yet filled. We're still receiving orders. I think the kind of the general guidance we gave in this call of around $1 million plus of Synchrony system sales per quarter seems very reasonable. And that obviously it's a lower ASP product in the near $200,000 range. And so that's something that we're shipping several of them out each quarter.

    在系統端方面,包含 Synchrony 與機器人系統兩者的組合。就 Synchrony 而言,我們已收到、也仍在收到一些尚未交付的訂單。我們仍持續接單。我認為我們在本次電話會議中給出的指引——每季約 100 萬美元以上的 Synchrony 系統銷售——是非常合理的。而這顯然是短期內 ASP 較低的產品,接近 20 萬美元的區間。因此我們每季會出貨好幾套。

  • On the system side, we are kind of the guidance -- kind of predicated on one system revenue recognition in each of the third and fourth-quarter. We have obviously the GenesisX sale, which we expect to recognize revenue in the third-quarter and install shortly thereafter. But -- and then kind of we have still a backlog and we have kind of additional Genesis orders that can be recognized as they get delivered and installed. And so that's kind of where the guidance comes from.

    在系統端,我們的指引——基本上是以第三季與第四季各認列一套系統收入為前提。我們當然有 GenesisX 的銷售案,預期在第三季認列收入,並在不久後完成安裝。此外——我們仍有訂單積壓,也有額外的 Genesis 訂單,隨著交付與安裝完成即可認列。因此指引大致是基於這些因素。

  • Daniel Stauder - Analyst

    Daniel Stauder - Analyst

  • I appreciate that and thanks for the color. Just the next one on cash flow. It's great to get that update. But I was wondering if you could just parse out a little bit more in terms of granular assumptions, in terms of -- is there a certain revenue level? Are there any other specific improvements on the operating lines in order to get there? Just wanted to double hit on this and get any more commentary in terms of the cash flow. It'd be great.

    了解,謝謝補充說明。下一個問題關於現金流。能得到這個更新很棒。但我想請你們再更細緻地拆解一下假設:例如——是否有某個特定的收入水準?為了達成目標,在營運費用各項目上是否還需要其他具體改善?我只是想再確認一次,並聽聽你們對現金流方面更多的評論。會很有幫助。

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • Sure. So I'll see if Kim wants to add to anything, but kind of from a very high level, right, we do scenario analyses all the time with conservative models, base models, and -- to kind of to evaluate the business and how we see it going. The main drivers of our business right now are the three that were discussed in the prepared remarks predominantly, again, the adoption of our robotically steered catheters and then capital sales both through Synchrony and through GenesisX.

    當然。我先回答,看看 Kim 是否要補充;從很高層次來看,我們一直在做情境分析,包括保守模型、基準模型等——用來評估業務以及我們對其走向的看法。目前我們業務的主要驅動因素,主要就是在事先準備的發言中提到的三項:再次強調,機器人導引導管的採用,以及透過 Synchrony 與 GenesisX 的資本設備銷售。

  • When we look at the ramp in catheter adoption given what we believe we will achieve from a manufacturing perspective and just the existing demand out there for those catheters, given the robotic procedures taking place at this time, I expect that our catheter innovations will improve utilization, but even without taking that into account, and with very modest assumptions on the capital side and kind of essentially the same kind of $1 million a quarter or so of Synchrony and system sales in line with our historical, we get to breakeven in the first half of next year and cash flow profitability kind of at that point.

    當我們觀察導管採用的提升,考量我們認為在製造端可達成的成果,以及目前市場上對這些導管的既有需求(鑑於目前正在進行的機器人手術),我預期我們的導管創新將提升使用率;但即使不把這點納入考量,在資本端採取非常溫和的假設,並且 Synchrony 與系統銷售大致維持與歷史相符、每季約 100 萬美元左右,我們也能在明年上半年達到損益兩平,並在那個時間點左右達成現金流獲利。

  • And so it requires relatively modest assumptions to get to breakeven. We are obviously staying lean on our operating expenses given that, but that doesn't mean that we don't continue to invest in the things that are impactful. And so we're still advancing a broad R&D pipeline. We're advancing some clinical studies. We're obviously doing all the operating work and commercial work to launch these new products.

    因此,要達到損益兩平所需的假設相對溫和。基於此,我們顯然會在營運費用上保持精實,但這不代表我們不會持續投資於具影響力的事項。因此我們仍在推進廣泛的研發產品線。我們也在推進一些臨床研究。我們當然也在進行所有營運與商業化工作,以推出這些新產品。

  • And so we think kind of with that balancing act of how to manage the expenses and then letting the recurring revenue start to kind of incrementally grow with that, with the availability of catheters, we'll be in a breakeven position at the beginning, at the early periods of next year.

    因此我們認為,透過在費用管理上的這種平衡,同時讓經常性收入隨著導管供應可得性而逐步增長,我們將在明年初、也就是明年早期期間處於損益兩平的位置。

  • Daniel Stauder - Analyst

    Daniel Stauder - Analyst

  • DAnd just one quick one, and I'll squeeze in on MAGiC catheters. Great to see the progress here on this side of the business. I know you mentioned last quarter that some of your customers were seeing revenue per procedure above $5,000, even up to $8,000. So I just wanted to ask on these dynamics, are you seeing that to continue in some of the early accounts or just any other trends you're seeing would be fantastic?

    再快速問一個,我想插問 MAGiC 導管。很高興看到這一業務面的進展。我記得你們上季提到,有些客戶每台手術的收入超過 5,000 美元,甚至到 8,000 美元。我想就這些動態請教:在一些早期帳戶中,你們是否看到這種情況持續?或是你們觀察到的其他趨勢也請分享,會很棒。

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • Sure. So yes, obviously, kind of, the baseline when someone is adopting MAGiC is that they're using our QuikCAS device, that's a historical disposable device we've been selling for 20 years, plus now a MAGiC catheter, one of our catheters. And they can also then add to that if they want a robotic high density mapping catheter or other diagnostic catheters that we are now able to supply.

    當然。所以是的,顯然,當某個客戶開始採用 MAGiC 時,基本配置是使用我們的 QuikCAS 裝置——這是我們已銷售 20 年的歷史一次性耗材裝置——再加上一支 MAGiC 導管,也就是我們的其中一款導管。此外,如果他們需要,也可以再加上機器人用的高密度標測導管或其他我們現在能供應的診斷導管。

  • And in the US, our pricing is extremely consistent across sites. And so that number of -- in the $5,000 to $8,000-plus range is a very consistent ASP we're receiving per procedure for the disposables used in a procedure. And in other geographies, it varies depending on the country. And so there's a tip -- and typically in Europe, it's at lower levels, but that's kind of the level that you quoted were the levels in the US

    在美國,我們在各個院所的定價非常一致。因此,每台手術 5,000 到 8,000 美元以上的這個數字,是我們就單次手術所使用的一次性耗材所收到的、非常一致的 ASP。在其他地區,則會因國家而異。因此——通常在歐洲會較低一些,但你所引用的水準是美國的水準。

  • Daniel Stauder - Analyst

    Daniel Stauder - Analyst

  • Congrats on the progress.

    恭喜進展順利。

  • Operator

    Operator

  • Frank Takkinen, Lake Street Capital Markets.

    Frank Takkinen,Lake Street Capital Markets。

  • Nelson Cox - Senior Research Analyst

    Nelson Cox - Senior Research Analyst

  • Hey, this is Nelson Cox on for Frank. Wanted to start with the US GenesisX purchase. On the compatibility strategy, once you declare formal compatibility with that first X-ray manufacturer with the fall install, what's the path to other major OEMs? Does each need its own reference installation? Or does the first declaration shorten that work for the rest?

    嗨,我是 Nelson Cox,代替 Frank 發言。我想先從美國 GenesisX 的採購談起。關於相容性策略,一旦你們在秋季安裝後,宣布與第一家 X 光設備製造商正式相容,接下來要拓展到其他主要 OEM 的路徑是什麼?是否每一家都需要各自的參考安裝?還是第一次的相容性宣告會縮短後續其他廠商的工作?

  • And then on the at least five active programs you targeted for this year, is that something we should still be expecting? I think you had commented on maybe one being in the ASC setting, but just curious your thoughts there.

    另外,關於你們今年鎖定的至少五個進行中的專案,這件事我們是否仍應該期待?我記得你們曾提到可能有一個是在 ASC 場景,但想聽聽你們對此的看法。

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • Sure. Hi, Nelson. Thanks for the questions. And so on the X-ray compatibility side, we need to do the formal testing and there's a few stages of testing so we've already done various stages of testing with all of the large X-ray manufacturers and out there that initial phases of testing has gone well with all of the different X-ray manufacturers and that's what gives us confidence in GenesisX being able to serve as a robot that works compatibly, kind of broadly compatible with different X-rays in existing operating rooms.

    好的。嗨,Nelson。謝謝你的提問。關於 X 光相容性這一塊,我們需要做正式測試,而且測試分成幾個階段;我們已經和所有大型 X 光設備製造商完成了多個階段的測試,而這些初期階段在不同 X 光製造商那邊的結果都很順利,這也是我們對 GenesisX 能作為可相容運作的機器人、在現有手術室中與不同 X 光設備廣泛相容的信心來源。

  • But the last stage of testing is actual formal compatibility testing, where in the clinical environment, we're placing the robot with the X-ray and doing formal testing compatibility of the two together. Once we do that with X-ray manufacturer A's and model A X-ray, then that becomes a compatibility statement that lasts for any of those X-rays, right? So then any other hospital that wants to use GenesisX with that X-ray, we can point to that compatibility statement and give them the confidence that it works together.

    但最後一個階段的測試是實際的正式相容性測試:在臨床環境中,把機器人與 X 光設備一起配置,並對兩者的相容性進行正式測試。一旦我們用 X 光製造商 A 的某一款(型號 A)X 光完成這項測試,那就會形成一份相容性聲明,適用於該類 X 光設備,對吧?因此,任何其他想用 GenesisX 搭配該款 X 光的醫院,我們都可以引用這份相容性聲明,讓他們有信心兩者能一起運作。

  • And so that's really kind of this initial effort is with the three, four, five biggest X-ray manufacturers out there and making sure that kind of we have formal compatibility statements with their main X-rays and that we can kind of prove to the world and prove to our customer base that they are compatible in a regulatory-compliant fashion. And so that's the effort.

    所以,這項初期工作主要是針對市面上三、四、五家最大的 X 光製造商,確保我們能針對他們的主力 X 光設備取得正式的相容性聲明,並以符合法規要求的方式向市場、向客戶群證明它們彼此相容。這就是我們正在推進的工作。

  • We have kind of one of them, and that gets a little bit to your second question that, yes, we're still working. Obviously, the site in Italy is the second one that's actually an integrated X-ray that we've had other installs of Genesis in the past with. So we'll have kind of two X-rays working with GenesisX by the end of this year, 1 in Europe, one in the US, and we are still working.

    我們目前大概已經完成其中一家;這也部分回應你的第二個問題:是的,我們仍在推進。顯然,義大利的那個站點是第二個——那裡的 X 光是整合式系統,而我們過去也曾在那裡安裝過 Genesis。因此到今年年底,我們會有兩套 X 光能與 GenesisX 一起運作:歐洲 1 套、美國 1 套,而我們仍在持續推進。

  • There's a pipeline of several hospitals, including an ASC that are working on lease agreements, and those are with actually other X-rays than the first two that I mentioned. And so we are expecting a few installs by the end of this year. I hope we can get towards five, but we'll definitely have two and hopefully we'll have someone between that two and five by the end of this year installed and able to prove kind of work in the real world.

    目前有數家醫院的管線在推進中,包括一家 ASC,正在洽談租賃協議;而這些其實使用的是不同於我剛提到前兩套的其他 X 光設備。因此我們預期在今年年底前會有幾個安裝落地。我希望能朝五個靠攏,但我們肯定會有兩個;並且希望在今年年底前,能在兩到五之間再多一些完成安裝,並能在真實世界中證明其運作表現。

  • Nelson Cox - Senior Research Analyst

    Nelson Cox - Senior Research Analyst

  • And then maybe just on reoccurring gross margins, if I heard correctly, it sounds like the expectation is that sales are maybe around flat with the 66% through the end of the year. Maybe just remind us where you think these reoccurring margins can go into next year, as much as you can.

    另外,關於經常性(reoccurring)毛利率,如果我理解正確,聽起來你們的預期是銷售毛利率可能在今年剩餘時間大致持平、維持在 66% 左右。能否再提醒我們一下,展望明年你們認為這些經常性毛利率有機會提升到哪個水準?在你們能分享的範圍內即可。

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • So I would generally point us towards margins in the mid-70s as the robotic catheters become more and more a part of the overall revenue. And as we are manufacturing more of them, and so the overhead can be kind of laid out over a bigger base, we should be getting somewhere in the mid-70s, I'd say, as a kind of a margin that shouldn't be difficult for us to reach.

    一般而言,我會把我們的目標指向 70% 中段(mid-70s)的毛利率,因為機器人導管在整體營收中的占比會越來越高。而且隨著我們製造量增加,固定成本/製造間接費用可以分攤到更大的基礎上,我們應該能達到 70% 中段;我認為這會是一個我們不難達成的毛利率水準。

  • Operator

    Operator

  • Joshua Jennings, TD Cowen.

    Joshua Jennings,TD Cowen。

  • Joshua Jennings - Analyst

    Joshua Jennings - Analyst

  • Wanted to just punch in on the GenesisX sales funnel. Any updates there? I know you referenced the backlog in one of your answers, David, looking for just any quantitative levels of where the backlog stands now versus maybe this time last year. And then, the mix between new greenfield accounts versus replacements.

    我想追問一下 GenesisX 的銷售漏斗。這方面有任何更新嗎?David,你在其中一個回答裡提到積壓訂單(backlog);我想了解一些量化資訊:目前的 backlog 水位相較於去年此時如何?另外,新開發(greenfield)客戶與汰換/替換(replacement)之間的組合占比如何?

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • Sure. Let me kind of comment, I guess, qualitatively, it's been very, very refreshing having GenesisX available as a system. We are engaging with many hospitals and many accounts where just historically there would be no opportunity or the opportunity would be years in the future, and we can actually have tangible discussions about how to bring a GenesisX system in there, how it can fit without construction, how -- at certain accounts where there is questioning over the clinical value and there's interest.

    好的。我先從質性角度評論:能夠提供 GenesisX 這套系統,確實讓人耳目一新。我們正在與許多醫院、許多客戶接觸;在過去,這些地方要嘛完全沒有機會,要嘛機會要等好幾年之後才會出現;而現在我們可以就如何把 GenesisX 系統導入、如何在不需要施工的情況下融入現場進行具體討論;在某些客戶那裡,對臨床價值仍有疑問但也有興趣。

  • But there's also uncertainty, there's the ability to talk about lease agreements and kind of the lack of permanence of the system and that kind of get your foot in the door, try it and kind of let us prove the value once we're already there. And so it definitely has helped us significantly have discussions with many accounts, including some of the most kind of prominent hospitals and kind of out there where historically before that we just didn't have our foot in the door and we couldn't really advance discussions in a very tangible way. And so that's kind of been awesome.

    同時,在存在不確定性的情況下,我們也能談租賃協議,以及系統「非永久性」的特點——這有點像先把腳伸進門檻,先試用,等我們進駐後再由我們證明其價值。因此,這確實大幅幫助我們與許多客戶展開對話,包括一些最具指標性的醫院;在過去我們根本無法打進去,也很難以非常具體的方式推進討論。所以這點真的很棒。

  • It's been slow and the kind of the two, I'd say, macro challenges in translating that overall interest in communication into conversion of deals has been obviously getting GenesisX actually working in the real world. And so let's say a month, a month and a half ago, right, we announced the launch of a new robotic program in Hungary and we have still hospitals that are more comfortable moving forward with Genesis, just because Genesis is a proven robot that has worked reliably in the real world.

    不過進展仍然偏慢;我認為把整體的興趣與溝通轉化為成交,主要有兩個宏觀層面的挑戰:第一,當然是讓 GenesisX 真正在真實世界中運作起來。例如大約一個月到一個半月前,我們宣布在匈牙利啟動一個新的機器人計畫;目前仍有一些醫院更願意推進 Genesis,因為 Genesis 是已在真實世界中被證明、可靠運作的機器人。

  • They can speak to physicians that have used it and kind of -- and so you have that kind of that certainty that it is a real reliable system for real world use. We need to prove the same for GenesisX. I have no doubts that we will prove that, but until you don't show it, there's always some more of a question mark in customers' minds. And so that's kind of one big thing that we need to do.

    他們可以去和使用過的醫師交流,因此對其作為真實世界用途的可靠系統有那種確定性。我們也需要為 GenesisX 證明同樣的事情。我毫不懷疑我們能證明,但在你還沒展示之前,客戶心中總會多一個問號。所以這是我們需要完成的一個重大事項。

  • The compatibility with various X-rays is a barrier because there are some physicians, some hospitals that are willing to be the first, but the average hospital prefers not to be the first one to prove things like that. And then obviously also MAGiC supply is the other third kind of barrier. Everyone who adopts GenesisX knows that they are -- that they need kind of to use MAGiC.

    與各種 X 光設備的相容性是一個障礙,因為有些醫師、有些醫院願意當第一個,但一般醫院通常不希望自己成為第一個去驗證這類事情的單位。另外,MAGiC 的供應顯然是第三個障礙。所有採用 GenesisX 的客戶都知道——他們需要使用 MAGiC。

  • And we're still in the phase of kind of -- making sure we have enough MAGiC to cover all the existing demand, let alone future demand. And so I'd say those are the three structural things that we're working on. I think we're making good methodical progress on all three of them. And over the next few months, should be able to at least with some of the X-rays, with the MAGiC manufacturing ramp with demonstrating GenesisX at these first two installs, we should be able to kind of reduce those and allow for kind of a higher momentum of GenesisX commercialization.

    而我們仍處於一個階段:確保我們有足夠的 MAGiC 來滿足現有需求,更不用說未來需求。所以我會說,這三點是我們正在處理的三個結構性問題。我認為我們在這三方面都在以良好且有條不紊的方式取得進展。在接下來幾個月,隨著部分 X 光相容性進展、MAGiC 製造產能爬坡,以及在前兩個安裝點展示 GenesisX,我們應該能逐步降低這些障礙,讓 GenesisX 的商業化推進動能更高。

  • Joshua Jennings - Analyst

    Joshua Jennings - Analyst

  • And just, great download and thorough download again today on the catheter buildout and the pipeline. I just wanted to circle back on just the future of GenesisX. I know I might imagine that your team is not standing still. I mean, can you talk about your ultimate vision as we think a couple years out, just I mean, and how GenesisX could open up or how you could enhance the platform with increased automation, maybe more telerobotic capabilities.

    另外,今天關於導管擴建與產品管線的說明也非常精彩且相當詳盡,再次感謝。我想再回到 GenesisX 的未來發展。我知道我可以想像你們團隊不會停下腳步。我的意思是,當我們把時間拉到未來幾年,你能談談你們的終極願景嗎?也就是 GenesisX 如何能進一步拓展,或你們如何透過更高程度的自動化、也許更多遠端機器人(telerobotic)能力來強化這個平台。

  • And then how that all plays out in terms of potentially widening a competitive moat? It seems as if the electrophysiology community is warming up each quarter, each year to robotics having a bigger role in ablation and maybe other areas in the coming years. But maybe touch on continued advancement of GenesisX capabilities and also just the EP community's sentiment towards robotics and robotics technology going forward.

    然後,這一切在可能擴大競爭護城河方面會如何展開?看起來電生理(EP)社群每一季、每一年都更願意接受機器人在消融以及未來可能其他領域扮演更重要的角色。不過也請談談 GenesisX 能力的持續精進,以及 EP 社群對於機器人與機器人技術未來走向的觀感。

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • Sure. So, let's say the Heart Rhythm Society, that's probably what you have in your mind, because I remember seeing you there at the Heart Rhythm Society conference this last May, I believe. There was the Society for Cardiac Robotic Navigation had their symposium in the middle of HRS. It was a huge room, and I was nervous that it would be relative, or at least look very empty.

    當然。所以,先說心律學會(Heart Rhythm Society),你腦中想的應該就是這個,因為我記得今年五月左右在心律學會年會上看到你。心臟機器人導航學會(Society for Cardiac Robotic Navigation)在 HRS 期間的中段舉辦了他們的研討會。會場非常大,我原本很緊張,擔心相較之下會顯得人很少,或至少看起來會很空。

  • And we ended up having a great showing. It was clearly by far the largest showing we've had at an HRS conference for robotics that in any of my memory. And so we do see kind of that increased interest in that also. Kind of I think the innovations that we've been able to show and the ability to get multiple innovations actually to market and through regulatory approvals.

    結果我們的出席情況非常好。很明顯地,這是我記憶中在任何一屆 HRS 年會上,與機器人相關的活動中規模最大的一次。因此我們也確實看到這方面的興趣正在提升。我想這也與我們能展示的創新,以及能把多項創新真正推向市場並通過法規核准的能力有關。

  • I think there are many people who are recognizing that and that's why we're able to re-engage with some of these kind of preeminent hospitals in the US that you know, historically we haven't had the relationships with and have meaningful conversations and kind of plan for how to work together in much more meaningful ways. And so I think you'll hopefully see some of that over the coming months as those come to fruition.

    我認為很多人都注意到這一點,這也是為什麼我們能重新與美國一些頂尖醫院建立互動——你知道,過去我們在歷史上並沒有這些關係——並展開有意義的對話,進而規劃如何以更實質的方式合作。所以我希望你在接下來幾個月能看到其中一些成果逐步落地。

  • And what I kind of say in terms of that kind of, on the one hand, we've done a lot. On the other hand, it feels like we're still in the very beginning of what should be done in terms of robotic innovation for this field and to really realize the full potential. And a little bit like in my prepared remarks, I think about our room for progress in four big buckets.

    至於我對此的看法,一方面我們已經做了很多;但另一方面,感覺我們仍然處在這個領域機器人創新應該做的事情的非常早期階段,距離真正實現全部潛力還有很長的路。也有點像我在事先準備的發言中提到的,我把我們的進步空間分成四個主要面向。

  • And there's meaningful progress that is being made along each of -- in each of these four big buckets. The first is just again, increased accessibility. The easier you make it to adopt something, the better, and the more adoption you're going to get. GenesisX was a major step change versus Genesis and Niobe, but it still has some aspects which require kind of an actual installation and some aspects, cable -- some cable routing, some power cables. There's just, there are things still to be done there.

    而且在這四個主要面向上,每一項都正在取得實質進展。第一個是提升可及性。你讓採用變得越容易,就越好,也就會帶來越多採用。GenesisX 相較於 Genesis 與 Niobe 是一個重大的躍升,但它仍有一些部分需要實際安裝,還有一些部分涉及線纜——一些線路佈線、一些電源線。這些方面仍然還有事情可以做。

  • And we are excited by -- at EHRA this past year, we kind of did a little demo of a fully wireless battery operated, fully mobile system that would help in various ways in smaller rooms. You'd be able to park the robot in corners of the room so you could fit it in smaller rooms. It would be a much easier even install, you literally roll it off a crate into the room.

    我們也很振奮的是——在今年的 EHRA,我們做了一個小型展示:一套完全無線、電池供電、完全可移動的系統,能在較小的手術室中以多種方式提供幫助。你可以把機器人停放在房間角落,讓它能適配更小的空間。它的安裝也會更容易,你基本上就是把它從木箱裡推進房間即可。

  • And it, kind of, it's a much more elegant system. And so that's, kind of, there's room for continued innovation there. And as we think about things like neuro or other fields, there's even much more dramatic steps beyond that. And the second big area is the interventional catheters and so having kind of a continued pipeline of interventional catheters that are robotically steered.

    而且它在某種程度上是一個更優雅的系統。因此在這方面仍有持續創新的空間。當我們思考像神經科或其他領域時,甚至還有比這更大幅度的跨越。第二個主要領域是介入性導管,也就是持續建立由機器人操控導引的介入性導管產品管線。

  • Again, a robot is only as good as the catheters it drives. And so kind of there's a, you need to constantly think about how to innovate in that world. The third is, but then again, we've seen that things like the J&J catheter existed for 20 years and had a very long tail. So on the one hand, innovation is very important. On the other hand, there is such a value proposition to the robot that even when there wasn't innovation, you have a fairly sticky business given the value proposition of the robot.

    再說一次,機器人的好壞取決於它所驅動的導管。因此你必須持續思考如何在那個世界裡創新。第三點是——不過我們也看到像 J&J 的導管已經存在 20 年,並且有非常長的產品生命週期。所以一方面,創新非常重要。但另一方面,機器人的價值主張本身非常強,即使在沒有創新的時期,基於機器人的價值主張,你仍然會有相當黏著度的業務。

  • The third big area is how to make our robot multi-specialty. And that ties in with Robocath and the complementary mechanism of action and how to really make GenesisX plus/minus Robocath a multi-specialty robot. And then the fourth is kind of then what you were saying, how do you bring telerobotics? How do you bring automation?

    第三個主要領域是如何讓我們的機器人成為多專科平台。這與 Robocath 以及其互補的作用機制相關,也就是如何真正讓 GenesisX 加/減 Robocath 成為一個多專科機器人。第四個則是你剛才提到的:如何導入遠端機器人?如何導入自動化?

  • How do you bring augmented intelligence or artificial intelligence into the picture? And there are, there I'd say we're in our earliest phases but we have real tangible things there. Synchrony and SynX are approved and in use and, kind of, they're definitely a good technology platform now for that whole digital surgery effort and there's a whole pipeline there that in reality will take probably 10 years to realize fully the ideas that we have in our mind, but there will be many attractive stepping stones along the path with room for commercial impact along that journey.

    如何把增強式智慧或人工智慧帶入整體架構?在這方面我會說我們仍處於最早期階段,但我們確實有具體、可落地的成果。Synchrony 和 SynX 已獲核准並投入使用,而且它們現在確實是一個很好的技術平台,可支撐整個數位手術(digital surgery)推進工作;同時也有一整條產品/研發管線。實際上,要把我們腦中所有想法完全實現,可能需要大約 10 年,但在這條路上會有許多具吸引力的階段性里程碑,並且在過程中也有空間帶來商業上的影響。

  • Operator

    Operator

  • As there are no further questions at this time, I would now like to turn the call back over to David Fischel for the closing remarks. Please go ahead.

    由於目前沒有其他問題,我現在想把電話會議交回給 David Fischel 進行結語。請開始。

  • David Fischel - Chairman of the Board, Chief Executive Officer

    David Fischel - Chairman of the Board, Chief Executive Officer

  • Okay. Thank you for all the questions everyone and for your continued support. We'll continue working hard on your behalf and look forward to speaking again soon. Thank you.

    好的。感謝各位提出的所有問題,也感謝大家持續的支持。我們會持續為各位努力工作,並期待不久後再次交流。謝謝。

  • Operator

    Operator

  • Ladies and gentlemen, thank you all for joining and that concludes today's conference call. All participants may now disconnect. Thank you.

    各位女士先生,感謝大家參與,本日電話會議到此結束。所有與會者現在可以斷線。謝謝。